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Epidemiology of rare cutaneous malignancies in the general population is poorly documented. This descriptive
study aimed to estimate the incidence and trends of all skin malignancies between 1989 and 2005. Data on skin
tumors were extracted from the Netherlands Cancer registry (except for basal cell carcinoma (BCC) data—only
available from Comprehensive Cancer Centre South) and categorized according to the International
Classification of Diseases for Oncology, third edition, codes. Age-standardized incidence rates (European
standardized population rate, ESR) per 100,000 person-years were calculated per year and for the period
between 2001 and 2005. Estimated annual percentage changes (EAPCs) were estimated by Poisson regression
models. A total of 356,620 skin tumors were diagnosed between 1989 and 2005. Excluding BCC, squamous cell
carcinoma (SCC), and melanoma, the remaining skin tumors constituted about 2% of all skin malignancies. The
incidence of melanoma showed the steepest increase (EAPC, 4.0%), and ESR was close to that observed for SCC
(EAPC, 2.3%) between 2001 and 2005 (17.1 versus 19.6). Hematolymphoid tumors (ESR¼ 0.74) were mainly
cutaneous T-cell lymphomas (60.8%). No significant increases in incidence were observed for lymphomas, and
appendageal, fibromatous, and myomatous carcinomas during 1989–2005. In addition to keratinocytic cancers and
melanoma, there is a wide variety of skin tumors that constitute o2% of all skin malignancies. The incidence of
UV-related skin tumors increased significantly and more steeply than did those of other skin malignancies.
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INTRODUCTION
Cutaneous malignancies are often categorized in nonmela-
noma skin cancer (NMSC) and cutaneous melanoma. NMSC
is commonly used to address basal cell carcinoma (BCC) and
squamous cell carcinoma (SCC), which are keratinocytic
cancers, but the category of NMSC comprises a wide variety
of skin tumors.
The incidence of skin tumors varies geographically and is
relatively well documented for melanoma, SCC, and to a
lesser extent for BCC in different international samples of the
general population (Katalinic et al., 2003; Christenson et al.,
2005; Brewster et al., 2007; Hoey et al., 2007). The
frequency of occurrence of the less common cutaneous
malignancies such as cutaneous B-cell and T-cell lympho-
mas, soft tissue sarcomas (for example, dermatofibrosarcoma
protuberans (DFSP)), sebaceous carcinoma, and Merkel cell
carcinoma is poorly documented. The studies that mention
the incidence rates of these rare skin malignancies are mainly
using data from the Surveillance, Epidemiology and End
Results (SEER) program, which registers pathology reports of
nine areas that cover about 10% of the US population
(Swetter et al., 2005; Morton et al., 2006; Criscione and
Weinstock, 2007; Rouhani et al., 2008; Bradford et al.,
2009). Currently, there are over 16.5 million Dutch citizens,
of whom the majority is white. The Netherlands Cancer
Registry registers all their pathologically confirmed cancers
since 1989. According to the Netherlands Cancer registry
(www.ikcnet.nl), skin cancers (excluding BCC) rank fourth
among the most common cancers in the Netherlands, with
9,681 cases in 2007, but mortality is low (European
standardized mortality rate¼0.3 per 100,000 person-years).
To our knowledge, this is the first population-based study to
provide incidence rates for all the major subtypes of skin
cancers. Other studies have mainly focused on BCC, NMSC,
and melanoma (Hannuksela-Svahn et al., 1999; Boi et al.,
2003; Katalinic et al., 2003; Omari et al., 2006; Sng et al.,
2009).
The objective of this descriptive epidemiological study is
to provide absolute numbers and incidence rates of all skin
cancer groups and their trends between 1989 and 2005 in the
general Dutch population.
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RESULTS
In total, an absolute number of 356,620 cutaneous malig-
nancies were registered in the Netherlands Cancer Registry
between 1989 and 2005 (including the first primary BCCs
from only one registry). The overall European standardized
population rate (ESR) was 126.31 per 100,000 person-years,
including the estimated first primary BCC rate for the Dutch
population.
In men and women, the ESR of cutaneous malignancies
(excluding BCC) in 2005 was 52.4 and 39.2 per 100.000
person-years, respectively. For the year 2005, the ESR of all
skin tumors except BCC among people aged 60 years or more
was 27.4 and that among people younger than 60 years of
age was 16.5 per 100,000 person-years.
Basal cell carcinoma
In the Netherlands, the estimated absolute number of people
with first primary BCC (International Classification of
Diseases for Oncology, third edition (ICD-O3) morphology
codes 8090–8110) that occurred between 1989 and 2005 was
254,157 (on the basis of an extrapolation of age-specific rates
in the Comprehensive Cancer Centre South to the Dutch
population), reflecting 70.9% of all skin cancers in the
general population of the Netherlands between 1989 and
2005. Of the BCC patients, 49.1% were male and had a
median age of 67 years. In the 5-year period between 2001
and 2005, the ESR of first BCC was 87.5 per 100,000 person-
years and the estimated annual percentage change (EAPC)
was 3.1% (95% confidence interval (CI) 3.0, 3.2) between
1989 and 2005.
Squamous cell carcinoma
The absolute number of SCCs, which is, similar to BCC, a
keratinocytic cancer, was 57,915 in the study period,
representing about 16% of skin cancers, including first primary
BCCs. The median age was 75 years and 62% of patients with
SCC were men. More than half of all non-BCC skin cancers
were SCC and its ESR was B20 (Table 1). The age-adjusted
EAPC was 2.3% per year and the ESR increased from about 15
to more than 20 between 1989 and 2005 (Figure 1).
Melanoma
In the 16-year study period, 38,647 melanomas were
registered, comprising about 11% of all skin malignancies
including first primary BCCs (Table 1). The median age of
melanoma patients was 53 years and the majority of patients
were women (except for desmoplastic melanomas in which
the majority was male patients). The ESR of melanoma was
17.1 between 2001 and 2005, roughly double that of 1989
with an EAPC of 4.0% (95% CI 3.8–4.2).
Of the different histological subtypes of melanoma,
superficial spreading melanomas were the most commonly
registered (54.1% of all melanomas) with an ESR of more than
10 per 100,000 person-years (Table 2). Nodular melanomas
Table 1. European standardized incidence rates for skin cancers in the Netherlands, 1989–2005
Groups of
(invasive) skin
tumors1 ICD-O3 codes
Total no.
tumors
(1989–2005)
Median
age (25–75
percentile)
Percentage
of men
Percentage of
total non-BCC
skin cancers
(1989–2005)2
ESR per
100,000
person-years
(2001–2005)
Keratinocytic tumors
(squamous cell
carcinomas only)2
8050–8052
8070–8078
8082–8084
57,915 75 (66–82) 62.2 56.5 19.61
Melanocytic tumors 8720; 8721; 8722; 8723; 8730; 8740; 8741; 8742;
8743; 8744; 8745; 8761; 8770; 8771; 8772; 8780
38,647 53 (40–66) 41.5 37.3 17.11
Appendageal tumors 8140; 8143; 8190; 8200; 8230; 8260; 8310; 8390;
8400; 8401; 8402; 8403; 8407; 8408; 8409; 8410;
8413; 8420; 8430; 8480; 8481; 8542
1,258 72 (60–81) 51.0 1.23 0.43
Hematolymphoid
tumors
9590; 9591; 9596; 9671; 9673; 9675; 9680; 9684;
9687; 9689; 9690; 9691; 9692; 9693; 9697; 9699;
9700; 9701; 9702; 9705; 9708; 9709; 9714; 9718;
9719; 9731; 9734; 9741; 9754; 9756
2,020 66 (53–76) 57.7 1.97 0.74
Soft tissue tumors 8800; 8801; 8804; 8805; 8810; 8811; 8830; 8832;
8833; 8840; 8850; 8890; 8891; 8894; 8910; 8982;
9120; 9133
1,390 45 (33–65) 54.2 1.36 0.50
Neural tumors 8240; 8246; 8247; 9503; 9540; 9560; 9580 723 76 (68–83) 39.1 0.71 0.29
Other skin tumors 8560; 8562; 8570; 8575; 8980 31 80 (65–87) 54.8 0.03 0.01
Skin tumors NOS 8000; 8001; 8004; 8010; 8011; 8012; 8020; 8021;
8030; 8031; 8032; 8033; 8041
479 74 (64–82) 55.7 0.47 0.12
Abbreviations: BCC, basal cell carcinoma; ESR, European standardized incidence rates; ICD-03, International Classification of Diseases for Oncology, third
edition; NOS, not otherwise specified; WHO, World Health Organization.
1Skin cancer groups according to WHO (LeBoit et al., 2006).
2BCC were excluded because only data on first incident BCC were available from the registry of the Comprehensive Cancer Centre South and not on total
number of tumors as for other tumor groups (available from all comprehensive registries of the Netherlands Cancer Registry).
1808 Journal of Investigative Dermatology (2010), Volume 130
C Holterhues et al.
Incidence of All Skin Cancers
comprised 15% of all registered melanomas, with an ESR of
2.36. A total of 1,280 lentigo maligna melanomas (3.3% of all
melanomas) were diagnosed between 1989 and 2005.
Patients with a lentigo maligna melanoma had a median
age of 71 years and were 15–20 years older than those
diagnosed with a nodular or superficial spreading subtype.
The ESR of the remaining specific melanoma subtypes ranged
between 0.02 and 0.16 per 100,000 person-years.
Hematolymphoid tumors
A total of 2,020 cutaneous hematolymphoid tumors were
diagnosed and confirmed by pathology reports in the
Netherlands between 1989 and 2005. In the period
2001–2005, the ESR of these malignancies was 0.74 (Table 1)
and the incidence remained stable during the study period,
after adjusting for age (Figure 1). Of the hematolymphoid
tumors, 60.8% were T-cell and natural killer cell lymphomas,
33.4% were of B-cell origin, and the remaining were
nonspecified tumors. About 60% of the cutaneous T-cell
lymphomas (CTCL) were classified as mycosis fungoides
(with an ESR of 0.20 per 100,000 person-years), 7.9% were
primary CD30þ lymphomas, and 3.1% of the patients with
CTCL had Se´zary syndrome (Table 2). Of the cutaneous
B-cell lymphomas (CBCL), diffuse large and follicular B-cell
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Year of diagnosis
Appendageal tumors, EAPC 1.4% (95%CI: 0.3%; 2.5%)
Squamous cell carcinoma, EAPC 2.3% (95%CI: 2.2%; 2.5%)
Cutaneous malignant melanoma, EAPC 4.0% (95%CI: 3.8%; 4.2%)
Hematological tumors, EAPC 0.8% (95%CI: –0.1%; 1.7%)
Soft tissue tumors, EAPC 0.8% (95%CI: –0.3%; 1.9%)
Neural skin tumors, EAPC 5.1% (95%CI: 3.5; 6.6%)
Other skin tumors, EAPC –0.6% (95%CI: –10.5%; 9.4%)
Skin tumors, not otherwise specified, EAPC –2.1% (95%CI: –3.9%; –0.2%)
Figure 1. Trends in incidence of skin cancer in the Netherlands, excluding basal cell carcinomas, 1989–2005.
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Table 2. European standardized incidence rates for the most common subtypes of skin cancers in the Netherlands,
1989–2005
Groups of (invasive)
skin tumors1 ICD-O3 codes
Total number
of tumors
(1989–2005)
percentage
within groups
Median age
(25–75
percentile)
Percentage
of men
ESR per 100,000
person-years
(2001–2005)
Melanomas
M NOS 8720 8,790 (22.7%) 53 (40–67) 41.8 2.91
Nodular M 8721 5,786 (15.0%) 57 (44–71) 48.5 2.36
Superficial spreading M 8743 20,911 (54.1%) 50 (39–62) 39.2 10.55
Lentigo maligna M 8742 1,280 (3.3%) 71 (61–79) 40.9 0.53
Acrolentiginous M 8744 334 (0.9%) 62 (52–74) 38.6 0.16
Desmoplastic M 8745 84 (0.2%) 66 (56–78) 57.1 0.04
M from pre-existing lesion 8740; 8741; 8761; 8780 86 (0.2%) 54 (38–68) 37.2 0.02
Other M 8722; 8723; 8770; 8771; 8772; 8730 1,376 (3.6%) 60 (46–72) 45.8 0.56
Soft tissue tumors
Fibrosarcomas 8810; 8811; 8830 137 (9.9%) 74 (65–82) 65.7 0.03
Dermatofibrosarcoma protuberans 8832; 8833 1,066 (76.7%) 41 (31–53) 52.2 0.39
Leiomyosarcoma 8890; 8891; 8894; 8910 119 (8.6%) 64 (51–77) 61.3 0.06
Others 8800; 8801; 8804; 8805; 8840; 8850;
8982; 9120; 9133;
68 (4.9%) 77 (66–84) 50.0 0.02
Appendageal tumors
Sebaceous glands 8410 296 (23.5 %) 74 (63–81) 58.1 0.1
Sweat glands 8400; 8402; 8403; 8407; 8408; 8409 413 (32.8%) 72 (59–82) 48.2 0.15
Extramammary Paget disease 8542 117 (9.3%) 74 (66–82) 57.3 0.04
Others and NOS 8140; 8413; 8143; 8190; 8200; 8230;
8260; 8310; 8390; 8401; 8420; 8430;
8480; 8481
432 (34.3%) 69 (57–80) 47.0 0.14
Neural tumors
Merkel cell carcinoma 8240; 8246; 8247 712 (98.5%) 77 (68–83) 38.8 0.29
Other 9503; 9540; 9560; 9580 11 (1.5%) 62 (47–78) 63.6 0.00
Hematolymphoid tumors
B-cell L 69 (54–79) 51.4 0.26
Diffuse large B-cell L 9675; 9680; 9684; 9731; 9734 385 (19.1%) 72 (61–82) 47.3 0.13
Follicular L 9690–9697 136 (6.7%) 62 (52–76) 55.9 0.05
Marginal-zone B-cell L 9699; 9671 122 (6.0%) 59 (45–73) 57.4 0.07
Other B-cell L 9673; 9687; 9689 17 (0.8%) 66 (29–74) 64.7 0.01
T and NK-cell L 65 (52–74) 61.8 0.43
Mycosis fungoides 9700 742 (36.7%) 64 (53–73) 63.7 0.2
Se´zary syndrome 9701 38 (1.9%) 71 (65–79) 50.0 0.01
Primary cutaneous CD30+ T-cell L 9718 97 (4.8%) 59 (46–72) 62.9 0.09
Anaplastic large cell L 9714 48 (2.4%) 58 (42–71) 60.4 0.02
Others 9705; 9708; 9719 16 (0.8%) 69 (56–77) 68.8 0.02
NOS tumors 9702; 9709 293 (14.5%) 66 (50–76) 57.7 0.09
L, others, and NOS tumors 9590; 9596; 9591; 9741; 9754; 9756 126 (6.2%) 71 (57–80) 50.8 0.05
Abbreviations: ESR, European standardized incidence rates; ICD-03, International Classification of Diseases for Oncology, third edition; L, lymphoma; NOS,
not otherwise specified; M, melanoma; WHO, World Health Organization.
1Skin cancer groups according to WHO (LeBoit et al., 2006).
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lymphomas (38.0 and 24.9%, respectively) were the most
common subtypes. Patients with CBCL were roughly 5 years
older than those with CTCL (median age 64 versus 69 years).
Except for diffuse large BCL and Sezary syndrome, the
majority (between 55.9 and 68.8%) of patients were male for
each of the subtypes of hematolymphoid tumors.
Other rare skin cancer subtypes
World Health Organization (WHO) groups of cutaneous
malignancies that were registered more than 1,000 times
during the study period were appendageal and soft tissue
tumors (1,258 and 1,390, respectively), with an ESR of more
than 0.40 for both subtypes (Tables 1 and 2). In total, 723
neural tumors of the skin were recorded (ESR¼0.29). In
contrast to the soft tissue tumors, the incidence of appenda-
geal and neural tumors increased significantly by 2.8 and
2.3% annually, respectively, during the 16-year study period
(Figure 1).
More than three quarters of the soft tissue tumors of the
skin were DFSP (1,066 Dutch patients between 1989 and
2005) with an ESR of 0.39. Almost all neural tumors were
Merkel cell carcinomas. About a third of the appendageal
tumors were recorded to derive from the sweat glands
(ESR¼0.1) and a quarter from the sebaceous glands.
Extramammary Paget disease was registered in 117 Dutch
people between 1989 and 2005. Appendageal and neural
tumors mainly occurred among people aged 70 years or
older, whereas the median age at diagnosis of cutaneous
sarcomas was 45 years (Table 1). Less than 40% of patients
with Merkel cell carcinoma were male.
Between 1989 and 2005, less than 0.5% of the recorded
skin cancers were without a pathology specification and their
proportion decreased significantly (2.1% annually (95% CI
3.9, 0.2)) over time.
DISCUSSION
Among the B15 million Dutch citizens, more than 350,000
skin malignancies have occurred between 1989 and 2005. It
was estimated that one out of six Dutch citizens will develop
a skin tumor in their lifetime (de Vries et al., 2009). The
keratinocytic skin cancers (BCC and SCC) and melanoma
together comprise more than 98% of all skin tumors. The ESR
of these three cutaneous malignancies are comparable with
those reported previously from the same Dutch population
and from other Northern European countries (Hannuksela-
Svahn et al., 1999; Katalinic et al., 2003; Brewster et al.,
2007), but are substantially lower than that in geographic
regions such as Australia and parts of the United States (Stern,
1999). Between 1989 and 2005, the incidence rates of
melanoma and SCC steadily increased and almost doubled.
Interestingly, the rate of increase of melanoma seemed to
accelerate in the last decade and is closing in on the SCC
rates. Other UV-related skin cancers such as Merkel cell
carcinoma and appendageal tumors also increased signifi-
cantly and more rapidly than other non-UV-related tumors
such as cutaneous lymphomas and sarcomas. This discre-
pancy confirms the fact that changed UV-exposure patterns
may be the driving force behind the steep increase in types of
cutaneous malignancies that are known to be related to UV
exposure. This observation suggests that, besides a potential
influence of surveillance and awareness, there must be a true
increase in the occurrence of BCC, SCC, and melanoma and
not just a diagnostic shift (Levell et al., 2009).
Of the less common skin malignancies, CTCL, CBCL, DFSP,
appendageal tumors, and Merkel cell carcinoma had the
highest incidence rates. Our findings show remarkable
similarities to other studies, often from the United States using
the SEER data, despite differences in the distribution of
demographic characteristics and geographic locations. The
observed ESR of 0.43 for CTCL was in the range of reported
incidence rates from Western populations (0.13–0.90 per
100,000 inhabitants) (Weinstock and Horm, 1988; Morales
Suarez-Varela et al., 2000; Morton et al., 2006). In accordance
with the SEER data, CBCL accounted for just over a third of the
cutaneous lymphomas and the observed ESR was very close to
the one in a US study (Bradford et al., 2009). The incidence of
DFSP detected in this study (ESR¼0.39) and its stability over
time is comparable with that documented in four US studies
using the SEER data (Weinstock and Horm, 1988; Toro et al.,
2006; Criscione and Weinstock, 2007; Rouhani et al., 2008).
Both in our study and in the US population-based studies
(Agelli and Clegg, 2003; Hodgson, 2005), the incidence rates
of Merkel cell carcinoma were about 0.30 per 100,000
inhabitants, with an almost threefold increase over the past
two decades, which is primarily observed in elderly people.
The Dutch and the US incidence of sebaceous carcinoma
were comparably low and constant over time (about 0.10 per
100,000 person-years) (Dores et al., 2008; Dasgupta et al.,
2009). In accordance with our findings, the majority of these
patients were elderly Whites.
Our study presents a comprehensive overview of the
descriptive epidemiology of all WHO skin tumor groups
including estimates of specific rare cutaneous malignancies
in the same time period and region (except for BCC that was
only recorded in the Southeast of the Netherlands). More-
over, it supplements epidemiological data on rare skin tumors
from the SEER data and provides a European perspective on
the occurrence of these malignancies in a general population
sample. To minimize misclassification bias, which may have
been introduced because of the long study period, the tumors
were coded according to the ICD-O3 classification for skin
malignancies (Fritz et al., 2002; Working Group Report,
2005) and categorized into WHO skin tumor groups in
collaboration with a certified pathologist (Senada Koljenovic´).
Nevertheless, misclassification may have occurred, but the
percentage of skin tumors that were otherwise not specified
was only 0.47%, which is in concordance with international
observations, suggesting that the impact of this bias is limited.
By using many sources of information (pathology reports,
hospital discharge information, clinical records, etc), the
Dutch cancer registries have shown to include most cancers;
their records are assumed to be complete since 1989 (de
Vries et al., 2003). Still, some underreporting may have
occurred, as some skin cancers might have been treated
without being pathologically confirmed. For some of the skin
cancer types, stratified trend analyses were not possible
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because of the limited number of cases. No information by
ethnic background or skin color was available.
In summary, the keratinocytic cancers and melanoma
form the overwhelming majority of cutaneous malignancies.
The remaining skin tumors constitute about 2% of all
malignancies and are predominantly lymphomas, DFSP,
appendageal tumors, and Merkel cell carcinomas with
incidence rates comparable with those observed in the
United States. The incidence rates of UV-related skin tumors
increased significantly and more steeply than those of other,
non-UV-related, malignancies.
MATERIALS AND METHODS
In the Netherlands, all pathology laboratories are affiliated with the
PALGA foundation, which registers all histopathology and cyto-
pathology reports. The Netherlands Cancer registry, comprising nine
Comprehensive Cancer registries, receives weekly reports of PALGA
on all pathologically confirmed cancers since 1989, covering more
than 95% of all cancers in the Netherlands. Using ICD-O3 codes
presented in Table 1, skin tumors were extracted from the Nether-
lands Cancer Registry between 1989 and 2005, except for BCCs,
which were registered in the Comprehensive Cancer Centre South
only. According to the ICD-O3 classification (Fritz et al., 2002;
Working Group Report, 2005), skin tumors were grouped into
keratinocytic cancers (BCC and SCC excluding in situ lesions),
melanomas, appendageal, hematolymphoid, soft tissue, neural
tumors, and others and nonspecified malignancies, as suggested by
the most recent WHO classification of skin tumors (LeBoit et al.,
2006). Only invasive lesions were included in the analyses.
The absolute number of newly diagnosed cancers was recorded
(and estimated in the case of BCC) for the whole Dutch population.
Age-standardized incidence rates were calculated using the ESR and
expressed per 100,000 person-years for each year between 1989 and
2005 and for the last 5 years (2001–2005), separately.
For the most common malignancies in each of the WHO skin
tumor groups, we estimated the annual percentage change (EAPC) in
number of incident cases by constructing Poisson regression models
with a log-link, modeling the observed number of cases as a function
of year of diagnosis, adjusting for age, and using the ln(population
size) per age group and year as offset variable. The EAPC was
calculated with a 95% CI. P-values were two-sided and considered
significant if they were o0.05. The analyses were performed
using SPSS version 15.0 (SPSS Inc., Chicago, IL), using generalized
linear models.
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